Catalytically self-sufficient cytochromes P450 for green production of fine chemicals by Ciaramella, Alberto et al.
 1 
 
 
 
This is the accepted version of the following article: 
 
[Ciaramella, A., Minerdi, D., Gilardi, G. Catalytically self-sufficient cytochromes P450 for green production of 
fine chemicals, Rendiconti Lincei, July 2017, Volume 28, Supplement 1, pp 169–181], 
 
which has been published in final form at [https://link.springer.com/article/10.1007/s12210-016-0581-z] 
 
  
 2 
Catalytically self-sufficient cytochromes P450  
for green production of fine chemicals 
 
1Alberto Ciaramella, Daniela Minerdi and Gianfranco Gilardi* 
 
 
Department of Life Sciences and Systems Biology, University of Torino,  
Via Accademia Albertina 13, 10123 Torino, Italy 
 
 
 
 
 
Running title: Catalytically self-sufficient cytochromes P450 
 
Keywords: Cytochromes P450, heme reactivity, monoxygenases, self-sufficient enzymes, biocatalysis, 
drugs synthesis 
 
Corresponding author: Gianfranco Gilardi, Department of Life Sciences and Systems Biology, University 
of Torino, Via Accademia Albertina 13, 10123 Torino 
Tel: +39-011-6704593; Fax: +39-011-6704643; Email addess: gianfranco.gilardi@unito.it 
ABSTRACT  
 
This review covers our current knowledge on catalytically self-sufficient cytochromes P450.  
These enzymes present all the advantages of the regio- and stereo-selectivity of typical P450s combined with 
the fact that, due to the natural fusion with their reductases, their application in biocatalysis does not need the 
addition of other proteins: only NAD(P)H and substrate are needed to trigger catalysis. 
To this date only few catalytically self-sufficient P450s have been isolated from bacteria, fungi and plants. 
Their low number does not detract from their importance, as the reactions they catalyse and the turnover 
numbers of which they are capable (in some cases higher than 15,000 s-1) makes them highly relevant to the 
                                                             
1 This contribution is the written, peer-reviewed version of a paper presented by a  participant to the 
Conference ""Concepts in catalysis : from heterogeneous to homogeneous and enzymatic catalysis"  held at 
Accademia Nazionale dei Lincei in Rome on February 25-26 , 2016. 
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chemical and pharmaceutical industry. 
These enzymes will be covered in this review, together with their specific reactions relevant to the field of 
biocatalysis. 
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1. INTRODUCTION. 
 
Cytochromes P450 (P450s) are heme-thiolate enzymes representing a large superfamily of proteins widely 
diffused in organisms from all kingdoms of life including viruses (Table 1). They are characterized by an 
absorbance peak at 450 nm appearing when the heme is reduced and complexed with carbon monoxide 
(CO). They can perform a wide variety of regio- and stereo-selective reactions on a large range of substrates 
making them an attractive target as biocatalysts for green chemistry applications.  
 
Tab. 1. Number of named P450 sequences to date (Nelson 2009). 
ORIGIN 
NUMBER OF NAMED 
P450 SEQUENCES 
Animals  10,477 
Insects 6,119  
Mammals 1,666  
Other vertebrates 1,344  
Non-insect invertebrates 1,348  
Plants  13,978 
Fungi  7,873 
Protozoa  602 
Bacteria  2,156 
Archaea  52 
Viruses  28 
TOTAL  35,166 
 
This review will concentrate on plant, fungal and bacterial catalytically self-sufficient P450s that are most 
relevant to chemical catalysis applications. We will also consider protein engineering approaches, by random 
mutagenesis on residues of the catalytic site as well as by rational design and fusion of different P450 
catalytic domains with various reductase domains to obtain catalytically self-sufficient chimeric enzymes. 
Here the gene of P450 redox partner and of the heme domain from different P450s are fused together in a 
single gene producing a single polypeptide chain capable of independent catalysis, enhancing the 
biotechnological potential of the natural enzymes (Gilardi et al. 2002, Sadeghi et al. 2013). 
 
2. P450 REACTIVITY. 
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P450s act as terminal monooxygenases performing reactions involving the transfer of one atom 
from molecular oxygen to X-H bonds, where X may be the –C, -N or S of a substrate, with the 
concomitant reduction of the remaining oxygen atom to water (Garfinkel 1958). The reaction uses 
the reducing power of NAD(P)H according to the scheme:  
Reaction 1:  RH + O2 + NAD(P)H + H+  →  ROH + H2O + NAD(P)+ 
Hydroxylation is the most common reaction carried out by P450s, but a wide range of other possibilities also 
exist, as shown in Figure 1. These include the formation of dicarboxylic acids from alkanes, epoxidations, N-
, S- and O-dealkylations, dehalogenations, peroxidations and N-oxide reductions (Guengerich and Munro 
2013).  
 
FIGURE 1. Known reactions described for P450s. (Adapted from Isin and Guengerich 2007) 
 
Moreover, these reactions can be performed on a wide spectrum of substrates owing to the highly flexible 
substrate recognition sequences (SRS) present on their 3D structure (Gotoh 1992). Figure 2 shows the 
localisation of the SRS in the P450cam (CYP101A1).  
 
 6 
 
FIGURE 2. SRSs regions in the P450cam (CYP101A) X-ray structure (PDB 2CPP) (Poulos et al. 1987).  
 
The wide range of reactions listed above, combined with the large spectrum of substrates covered by 
different natural and engineered P450s, makes them a good target for the production of fine chemicals by 
environmentally sustainable means (Valetti and Gilardi 2004, Gilardi and Di Nardo 2016). 
In all cases the P450 reactivity must be sustained by an electron supply that ultimately is 
represented by NAD(P)H. This normally provides the electrons through a reductase partner or a 
domain that in turns binds and delivers two electrons to the P450 heme. The mode of electron 
supply forms the basis for a classification of these enzymes as illustrated in the following section.  
 
3.  P450 CLASSIFICATION BASED ON ELECTRON TRANSFER PARTNERS. 
 
Redox protein partners or reductases are key for providing the electrons required to support the 
P450 catalytic cycle allowing to deliver the two required electrons one at the time to the different 
intermediates in the P450 catalytic cycle (Gilardi and Di Nardo 2016, Sevrioukova et al. 1999). For 
some P450s, its reductase is one or more separate proteins made of one or more domains. In some 
cases the reductase domain is fused with the P450 domain in one polypeptide chain. There, the 
enzyme is self-sufficient, in that only NADPH addition is needed to trigger catalysis without the 
need of adding separate proteins. Only very rarely P450s have been found to achieve the reductive 
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activation of oxygen without involving any redox partner (Toritsuka et al. 1997 and Stundl et al. 
1998). 
In early days, P450 had been classified in only two classes, class I and class II, but to this date, 
many more P450s have been discovered with a variety of electron deliver systems, leading to a new 
classification that comprises ten different classes (Hannemann et al. 2007), from class I to class X. 
Figure 3 systematically shows all classes of P450s, but here in the text we will only describe classes 
VII to X that correspond to the self-sufficient systems. 
Class VII P450s are bacterial, soluble and cytosolic multi-domain enzymes. A single polypeptide 
chain comprises a heme containing P450 domain at N-terminus as well as a FMN containing 
reductase domain at the C-terminus. The reductase domain has been found to be closely related to 
the phthalate oxidase reductase (PFOR) (De Mot and Parret 2002). Class VII P450 are considered 
self-sufficient enzymes, as they are able to perform reactions in the presence of the only electron 
donor, without the necessity of a redox partner (Hannemann et al. 2007). This class is well 
represented by the CYP116B subfamily, that they take part in reactions involving substrates such as 
thiocarbamate pesticides relevant from a bioremediation point of view (Warman et al. 2012). 
Substrates as alkanes, aromatic compounds and terpenes were also found to be involved in different 
oxidation reactions involving these enzymes (Yin et al. 2014). 
Class VIII encompasses cytosolic self-sufficient P450 enzymes, both prokaryotic and eukaryotic. 
Here a single polypeptide chain contains the heme domain at the N-terminus while a reductase 
domain homologous to the eukaryotic cytochrome P450 reductase (CPR), containing both FAD and 
FMN subdomains is present at the C-terminus.  
This class is represented by CYP102A1 from Bacillus megaterium an important model P450 enzyme that 
will be described in details later.  
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FIGURE 3. Classification of P450s on the basis of their electron transfer partners or requirements. 
Abbreviation:  Fdx (iron–sulfur-cluster: [2Fe–2S], [3Fe–4S], [4Fe–4S], [3Fe–4S]/[4Fe–4S] type); 
FdR/FAD, Ferredoxin reductase (FAD); CPR, cytochrome P450 reductase (FAD, FMN); Fldx, 
Flavodoxin (FMN); OFOR, 2-oxoacid: ferredoxin oxidoreductase (thiamin pyrophosphate, [4Fe–
4S] cluster); PFOR, phthatate-family oxygenase reductase (FMN, [2Fe–2S] cluster).   
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Also the self-sufficient P450 from ascomycete fungus Fusarium oxysporum belongs to class VIII: 
CYP505A1 (P450 foxy). It catalyses C8-C18 fatty acids hydroxylation at ω-1- ω-3 as the bacterial 
counterpart BM3 (Nakayama et al. 1996) as described later. 
Class IX comprises nitric oxide reductase from Fusarium oxysporum CYP55, also known as 
P450nor (EC 1.7.99.7), that is a particular cytochrome involved in the denitrification process.   
Only a few additional members of this class have been characterized (Zhang et al. 2001 and Kudo et 
al. 1996). These enzymes do not have monooxygenase activity, but they show a unique electron 
transfer chain system. P450nor uses NADH directly as an electron donor without the need of a 
redox partner to reduce two molecules of nitric oxide (NO) to nitrous oxide (N2O). This is to protect 
the fungus from NO inhibition, especially when dioxygen becomes limiting (Daiber et al. 2005). 
This is a unique reductive process in P450 reactivity. Some real technological application regarding 
this class of enzymes has recently been proposed (Garny et al. 2016). 
Class X comprises a P450-only system similar to class IX but rather particular features. It 
comprises the CYP74 family. CYP74A (AOS) is an allene synthase as well as CYP74B/C that is a 
fatty acid hydroperoxide lyase (Shibata et al. 1995). CYP74(DES) (Itoh and Howe 2001), that is 
crucial in the oxidative metabolism of polyunsaturated fatty acid hydroperoxides, that are converted 
into different oxylipins with important roles in plant growth (Hou et al. 2016).  
The catalytic features in biosynthesis and the function of these enzymes are shared in mammal 
P450s prostacyclin synthase and thromboxane synthase, that are involved in the arachidonic acid 
cascade. 
The peculiar feature of these enzymes resides in the fact that they do not require O2 or NAD(P)H 
for their reactions, but rather they use acyl hydroperoxide that is the oxygen donor as well as the 
substrate (Lau et al. 1993), forming new carbon oxygen bonds. 
 
4.  CATALYTICALLY SELF-SUFFICIENT P450s. 
 
Catalytically self-sufficient cytochromes P450 are included in classes VII to X. Class VII and VIII 
P450s show a reductase naturally fused to the P450 catalytic domain, therefore for these enzymes to 
function and perform catalysis is only necessary to add NAD(P)H and substrate, without the need to 
add other electron transfer proteins. This represents a distinct advantage from the catalytic and 
biotechnological point of view. To date only very few self-sufficient P450s have been found, 
mainly deriving in bacteria, fungi and plants. Nevertheless, inspired by the protein architecture of 
these self-sufficient P450 systems, different kinds of artificial fusion proteins have been constructed 
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with protein engineering approaches (Sadeghi and Gilardi 2013). Here we report the most relevant 
systems for each of these groups.  
 
4.1.  Bacterial enzymes 
CYP102A1 from Bacillus megaterium 
The most intensively studied bacterial P450 enzyme is CYP102A1 (Miura and Fulco 1974), known as P450 
BM3 isolated from the soil bacterium Bacillus megaterium. This self-sufficient P450 is soluble and is 
composed of a eukaryotic-like P450 reductase containing a FAD and FMN subdomains fused to a P450 
domain. The solubility is a great advantage and it makes P450 BM3 a very good model system for electron 
transfer studies. It was one of the first bacterial P450 enzymes to be crystallized both in its open, substrate-
free, and closed, substrate-bound, forms. Due to its high homology to the class II human drug-metabolizing 
enzymes, for many years this enzyme has been used as a paralog for the eukaryotic enzymes. 
It is able to hydroxylate a range of fatty acids at ω-1, ω-2 and ω-3 positions, displaying the highest 
monooxygenase activity of any P450 system investigated to date, that is in the region of 17000 s-1 
for the substrate arachidonate (Munro et al. 2002). Its catalytic activities, combined with 
mutagenesis studies, has produced enzymes suitable for drug metabolite production such as 
hydroxylation of diclofenac, ibuprofen and tolbutamide (Tsotsou et al. 2012, Sideri et al. 2013), as 
well as in the development of process-scale approaches (Di Nardo and Gilardi 2012), methane 
oxidation, and more generally has produced mutants with improved selectivity to allow the 
synthesis of fine chemicals (Whitehouse et al. 2012). Some of these mutants have also been 
characterized in details by X-ray crystallography (Di Nardo et al. 2016). Moreover, its FAD and 
FMN containing reductase (BMR) has been used to drive catalysis in artificial fusion systems 
(Sadeghi and Gilardi 2013, Astuti et al. 2004). 
 
The 116B subfamily  
CYP116B2, also referred as P450RhF, was the first enzyme in the 116B subfamily to be expressed 
and purified by Roberts et al. (2003). From the N- to the C-terminus, its reductase shows three 
distinct functional parts: a FMN-binding domain, a NADPH-binding domain and a [2Fe–2S] 
ferredoxin domain. Considering the general fold, the ferredoxin domain is supposed to be between 
the heme domain and the FMN-domain. Therefore, the electron transport is supposed to go from the 
primary electron donor (NAD(P)H) via the FMN and the [2Fe–2S] cluster of the reductase domain 
to the P450 domain.  
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In the same family is CYP116B3 that catalyses the o-dealkylation of 7-ethoxycoumarin producing 
7- hydroxycoumarin. In the presence of NADPH, it is also capable of hydroxylation towards 
aromatic hydrocarbons, naphthalene, indene, acenaphthene, toluene, fluorene, m-xylene and ethyl 
benzene (Liu et al. 2006).  
Recently, our laboratory has isolated a novel 116B cytochrome from Acinetobacter radioresistens 
growing on alkanes as a sole energy source. It can be used in the hydroxylation of long (C24-C36) 
and medium-chain (C14, C16) alkanes (Minerdi et al. 2015). At present, further analysis of P450 
domain are undergoing. Early experiments on the purified P450 domain are present in this paper for 
the first time and indicate the presence of the typical P450 spectroscopic features (figure 4). 
Moreover, a crystallization screening of the heme domain is being carried out.  
 
FIGURE  4. UV/Vis absorption spectra for purified 116B5 heme domain showing the purified 
oxidized enzyme (solid line), the dithionite-reduced enzyme (dashed line), and the reduced CO-
bound complex (dotted line). The CO-bound reduced difference spectrum and the SDS gel before 
and after the purification are shown in the inset.  
 
Other bacterial P450s 
Very recently two novel CYP102 from the bacterium Ktedonobacter racemifer have been 
characterized as Krac0936 and Krac9955 (Munday et al. 2016). Krac0936 mainly hydroxylates long 
saturated fatty acids at the ω-1 and ω-2 positions and cis,cis-9,12-octadecadienoic, as well as 
pentadecanoic acids. Krac9955 is able to oxidize the tridecanoic, tetradecanoic and pentadecanoic 
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acid oxidation at the ω-4, ω-5 and ω-6 positions, together with lower activity towards unsaturated 
fatty acids.  
Other closely related enzymes are CYP102A2 and A3 from Bacillus subtilis, (Gustafsson et al. 
2004) A5 (Chowdhary et al. 2007) from Bacillus Cereus and A7 (Dietrich et al. 2008) from Bacillus 
nicheliformis.  
CYP102D1 from Streptomyces avermitilis has been reported to be a class VIII self-sufficient 
enzyme. It catalyses fatty acid hydroxylation showing similar substrate preference profiles and 
kinetic properties with the CYP102 family (Choi et al. 2012). 
 
4.2. Fungal enzymes 
To date all fungal catalyically self-sufficient P450s have been found in the species Fusarium, in particular 
Fusarium oxysporum and Fusarium verticillioides. 
 
4.2.1 P450s from Fusarium oxysporum. 
CYP55: nitric oxide reductase. 
Nitrogen fixation or nitrification carried out by microorganisms represents the main step in the nitrogen 
cycle, a fundamental process necessary to support life and key to maintaining nitrogen homeostasis on Earth. 
The inverse process, called denitrification, has been well characterized in bacteria where the process occurs 
under anaerobic conditions and it involves four reducing steps involving the following enzymes (Shoun et al. 
2012): 
 
Reaction 2, nitrate reductase (dNar):   NO3- + 2H+ à NO2-  + H2O 
Reaction 3, nitrite reductase (dNir):   NO2-  + 2H+ à NO + H2O 
Reaction 4, nitric oxide reductase (Nor):  2NO + 2H+ à N2O + H2O 
Reaction 5, nitrous oxide reductase (Nos):  N2O + 2H+ à N2 + H2O 
 
Denitrification also occurs in fungi where the best studied system is the one of the ascomycete Fusarium 
oxysporum. Here the nitric oxide reductase activity is carried out by the cytochrome P450nor (Nakahara et 
al. 1993; Takaya and Shoun, 2000). 
P450nor belongs to family 55 (CYP55) and it is class a IX P450 (Hanneman et al. 2007). It was isolated 
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from the soil fungus Fusarium oxysporum as a heme enzyme with a lipoxygenase activity and typical P450 
spectral properties (Shoun et al. 1983). P450nor is widely diffused, mainly across the subdivision of 
ascomycotina (Shoun et al. 2012). It is present both in the mitochondria and in the cytoplasm of fungal cells 
and its molecular weight has been reported to range from 42 to 46 KDa (Nakahara et al. 1993; Usuda et al. 
1995; Zhang et al. 2001). CYP55 is able to use NADH as a direct electrons donor, according to a process that 
is very unusual in that the two electrons from NADH are transferred here simultaneously to the heme as a 
hydride ion. The reaction is divided into three steps. First substrate (NO) binds to ferric (Fe3+) P450nor to 
form a ferric-NO complex (reaction 6), then the Fe3+-NO is reduced with NAD(P)H to form the specific 
heme intermediate (Iheme) that shows a Soret peak at 444 nm (reaction 7), and finally it interacts with the 
second NO to form N2O (reaction 8). 
 
Reaction 6:  Fe3+  +  NO   à   Fe3+NO 
Reaction 7:  Fe3+NO  +   NAD(P)H   à  Iheme   +   NAD(P)+ 
Reaction 8:  Iheme + 2NO + 2H+ à N2O + H2O 
 
The chemical nature of the Iheme intermediate seems to be ferric-hydroxylamine radical complex (Daiber et al. 
2002). Direct electron transfer from NADH to the heme of P450nor was demonstrated by the resolution of 
the crystal structure of P450nor complexed with the NADH-analogue nicotinic acid adenine dinucleotide, 
NAAD (Oshima et al. 2004). The structure of the P450nor–NAAD complex showed a conformational 
change upon binding of NAAD since the entrance gate of the heme distal pocket is closed. Glu71, Arg64 and 
Asp88 form a salt bridge network to stabilize the protein structure (Umemura et al. 2004; Su et al. 2004). 
Nitric oxide reductase is employed for the quantification in solution of nitric oxide (Garny et al. 2014), 
biosensores development and research tools for the study of the biological roles of this important cell-
signalling molecule (Mur et al. 2006).  
The use of NO scavengers, toxic chemical compounds that could mask the NO function (Turpaev et al. 
2004), impaired the current in vitro research analysis of the biological role of nitric oxide. To overcome this 
limit, the use of an enzymatic system of NO reduction could be a valid option. A good candidate is 
represented by P450nor since it is monomeric, has a single domain and accept electrons directly from its 
cofactor NADH/NADPH. Garny and colleagues (2016) developed a novel, dual enzyme system co-
immobilizing on carboxyl-functionalized hyper-porous microspheres, the P450nor from Aspergillus oryzae 
and Bacillus megaterium glucose dehydrogenase with enzyme activity maintenance of 158% for P450nor 
and 104% for glucose dehydrogenase. The system is capable not only of continuously reduce NO but also to 
recycle the NADH cofactor through the action of glucose and glucose dehydrogenase. The NOR system 
reduces NO in a concentration-dependent manner and is able to maintain the cell viability when cytotoxic 
 14 
concentration of nitric oxide are used. 
 
CYP505: fatty acid hydroxylase. 
Another self-sufficient cytochrome P450 isolated from F. oxysporum is represented by P450foxy belonging 
to CYP505 family (Nakayama et al. 1996; Kitazume et al. 2000, 2002). This is a membrane bound enzyme 
composed of a N-terminal heme domain naturally fused to a carboxy-terminal reductase domain in a single 
polypeptide. Phylogenetic analysis of the heme domain provided evidence that it is the eukaryotic 
counterpart of the bacterial BM3. Pfoxy catalyzes the sub-terminal w-1 to w-3 carbons fatty acids 
hydroxylation. Redox equivalents given by NADPH go to the FAD and FMN cofactors present in the 
reductase domain and then to the heme. Since the heme and reductase domains are naturally fused, the 
turnover number of Pfoxy is one hundred-fold higher than the one of conventional class II P450s, with which 
shares the electron transfer mechanism (Kitazume et al. 2002).  
The hydroxylation on specific carbon atoms of aliphatic compound is important in industrial chemical 
synthesis. In fact, omega fatty acids terminally oxidized are useful for the synthesis of industrial compounds 
with pharmaceutical and commercial interests such as potential anticancer drugs, cosmetic intermediates, 
adhesives and bioplastics (Durairaj et al. 2015). Enzymatic hydroxylation of specific C-H bonds is an 
interesting solution since a specific carbon atoms are hydroxylated. Self-sufficient cytochromes P450 are 
ideal candidates for this kind of application since they do not depend upon P450 reductase, furthermore their 
high turn-over number allow their application in high-throughput catalytic systems development. 
Recombinant fungal Pfoxy expressed in Escherichia coli cells convert saturated fatty acids with a chain 
length from C7 to C16 that are present in waste lard and vegetable oils originating from recycling industry to 
their w-1 to w-3 hydroxy derivatives (Kitazume et al. 2008).  
 
4.2.1 P450s from Fusarium verticillioides.  
CYP505B1. 
Another member of class VIII, called CYP505B1 (Fum6p), has been identified in the filamentous 
ascomycete Fusarium verticillioides showing the highest aminoacid sequence identity with P450foxy (Seo et 
al. 2001). F. verticillioides is a maize pathogen that produces the mycotoxin fumonisin that can accumulate 
in infected maize and cause fatal animal diseases and human esophageal cancer (Sydenham et al. 1990). 
CYP505 is organized in the same way as P450foxy involved in the mycotoxin fumonisin biosynthesis (Seo 
et al., 2001). Fumonisin is a linear 20-carbon backbone, that has a polyketide origin, substituted at various 
positions with an amine, one to three hydroxyl, two methyl, and two tricarboxylic acid groups. Gene 
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disruption analysis revealed that FUM6 gene is required for fumonisin production and Northern blot analysis 
revealed that its expression is correlated with fumonisin production (Proctor et al. 2003). 
 
4.3. Plant enzymes. 
CYP74 family. 
Plant CYP74 is a family of self-sufficient cytochromes P450 belonging to class X with electron transfer 
properties very different from the typical P450s. They utilize an acyl hydroperoxide of the substrate both as 
the oxygen donor and as the substrate in which the new carbon-oxygen bonds are formed. Therefore, they do 
not require O2 or a NADPH-dependent cytochrome P450 reductase or NAD(P)H (Itoh and Howe 2001; Lau 
et al. 1993; Shibata et al. 1995) and have low CO affinity. To date class X P450s have not been found to be 
present in mammals. 
The CYP74 family comprises the allene oxide synthase (CYP74A), fatty acid hydroperoxide lyase 
(CYP74B, CYP74C) and divinyl ether synthase (CYP74D). CYP74A, B, C and D are present in the 
chloroplast membranes where they are key enzymes of the plant lipoxygenase pathway (Froehlich et al. 
2001).  
Fatty acid hydroperoxide lyase is an enzyme that cleaves hydroperoxides of polyunsaturated fatty acids to 
form short chain aldehydes and ω-oxoacid. It is a component of the oxylipin pathway and holds a central role 
in eliciting plant defence (Psylinakis et al. 2001). Allene oxide synthase is involved in the metabolic pathway 
that produces the plant growth regulator jasmonic acid from unsaturated free fatty acids (Vick and 
Zimmerman, 1984). Divinyl ether synthase converts hydroperoxides into the divinyl ethers (Grechkin and 
Hamberg, 1996). 
 
4.4. Artificial P450-reductase fusion systems produced by protein engineering 
The requirement of the addition of a redox partner protein to sustain P450 enzymatic catalysis is 
considered a bottle neck in biocatalysis due to the necessity of different components in solution, 
with a possible loss in efficiency and higher costs. This has motivated many works in which P450 
enzymes of biotechnological interest that are not natural fusion with their reductase have been 
engineered to produce artificial multi-domain systems. In this way the enzyme and a reductase of 
choice are fused at genetic level to produce a single polypeptide chain. As a result, the engineered 
protein comprises two domains: the catalytic P450 domain and the reductase electron transfer 
domain requiring only addition of NAD(P)H and substrate to perform catalysis. Many such 
constructs have been reported to date in the literature, where their advantages in terms of the 
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improvement of their catalytic properties, coupling efficiency and possibly solubility are reported in 
comparison with their separate parent enzymes (Sadeghi and Gilardi, 2013). In some cases, human 
P450 fusion proteins have been shown to be useful tools for the study of drug metabolism, with 
consequences of drug–drug interactions and the activation of carcinogens.  
The first fusion protein reported in literature in 1987 is the rat CYP1A1/rat NADPH CYP reductase 
system (Murakami et al. 1987) able to oxidise ethoxycoumarin. Rat reductase was successively 
used to build up chimeras with bovine (CYP17A1), dog (CYP2B11) and human (CYP3A4, 
CYP1A2) P450s (Shet et al. 1994, Fisher et al. 1992).  
A general approach called the “Molecular Lego” (Sadeghi et al. 2001, Gilardi et al. 2002) was then 
applied to P450 enzymes by fusing class II human P450s with the soluble reductase of Bacillus 
megaterium P450 BM3 (BMR), resulting in a soluble and self-sufficient system. Examples of such 
fusion systems are human CYP2E1 (Fairhead et al. 2005), CYP2C9, CYP2C19, CYP3A4 (Dodhia 
et al. 2006), CYP2A6, CYP2C6 and CYP4F11 (Ortolani 2012, Rua 2012) and monkey CYP2C20 
and dog CYP2D15 (Rua et al., 2010). The advantages reported for these chimeras are the activity, 
solubility and correct folding in absence of detergents, and the simple addition of NAD(P)H and 
substrate to trigger catalytic activity. Moreover, in a further step NAD(P)H was replaced by 
electrode surface that provides the electrons driving the catalysis without the use of costly cofactors 
(Sadeghi et al. 2011). 
Another example of artificial fusion systems is the CYP116B family. Nodate and colleagues (2006) 
have created a fusion protein with P450cam heme domain and the reductase domain of CYP116B2 
(P450RhF).  P450cam-RhFRed chimera shows 100% conversion of camphor to 5-exo-
hydroxycamphor and its specific recognition of substrates could be significantly enlarged by 
mutations in the different sites (Fowler et al. 2002). This chimera with Tyr96Phe mutation, 
combined with Tyr96Phe/Val247Ala mutations, has been studied with a high-throughput screening 
protocol by Robin et al. (2011), and was aimed at reaching the oxidation of useful molecules with 
an industrial application, such as terpenes α- and β-ionone relevant to the fragrance industry. 
 
5. APPLICATIONS OF P450s IN INDUSTRY: PERSPECTIVES 
 
The use of enzymes in industrial processes is a fast growing field that now is even more close to its 
maturity. Despite being attractive targets for catalysis, their wide application in industry still 
presents serious challenging due to a number of reasons. On one hand, biochemistry has made 
major advances in understanding their mechanisms, in controlling their proficiency and in 
 17 
producing high levels thanks to DNA recombinant methods and heterologous expression 
technologies (Roiban and Reetz 2015). 
Protein engineering both by rational mutagenesis methods and in vitro darwinian evolution 
strategies has offered a handle in improving their stability to temperature and pH, their resistance in 
organic solvent environments, their immobilisation on suitable supports. Moreover the growing 
legislative attention to the environment and demand for sustainable approaches to chemical 
synthesis has highlighted the intrinsic advantages in the use of enzymes as catalysts. In spite of their 
remaining limitations of possibly higher costs, more and more areas of applications have been 
uptaken in industry (Choi et al. 2015) 
The application of P450s in industry is mainly in the area of generation of drug metabolites and 
synthetic intermediates as they can produce fine chemicals at high grade of purity. Heterologous 
expression in Escherichia coli or insect cells allows to obtain recombinant enzymes that can be used 
to produce molecules for use in the pharmaceutical industry. The cofactor regeneration and the 
costs associated with it, as well as narrow substrate specificity, the limited solvent tolerance are 
some of limitations encountered in the use of P450s on industrial processes (O’Reilly et al. 2011, 
Urlacher and Girhard 2012). In some case a whole-cell approach has given the best solution for 
specific problems. In 2003 Aventis-Pharma and the CNRS (Gif sur Yvette, France) have 
demonstrated the feasibility of transferring a complex biosynthetic pathway from higher eukaryotes 
into microorganisms producing hydrocortisone in yeast (Szczebara et al. 2003). Here complex 
products have been synthetized, replacing long and expensive synthetic multi-step reactions. 
In 2006, P450 BM3 was implemented in the preparation of metabolites of propanolol (Otey et al. 
2006). The high catalytic activity of this enzyme is very attractive, and thus the random 
mutagenesis approach has been largely used in order to expand the range of the wild-type (WT) 
protein to include different substrates and create a new product. Many different high throughput 
screening methods have been proposed for discovering favourable random mutations in BM3 
mutants evolved to recognise specific substrates. One of such methods is represented by the alkali 
NAD(P)H assay that has allowed to identify mutants capable of specific reactions within a library 
of random mutants generated by error prone PCR (Gilardi et al. 2002, Di Nardo and Gilardi 2012).  
Rational mutagenesis studies on Trp96 conserved residue, shows a primary role in the heme 
coordination through some key hydrogen bonds (Munro et al. 1994 and Ravichandran et al. 1993).  
Substitution of Phe87 makes BM3 able to hydroxylate lauric and myristic acid, mainly at the ω-
position, that is not reached by the WT enzyme. Phe87Val combined with Ala82Phe mutation 
resulted in an increase in the active site space, allowing more substrate hydroxylation, while other 
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mutants (Cha et al. 2014) can make metabolites of non-steroidal anti-inflammatory drug diclofenac 
(mimic 4’- and 5’- P450s human metabolites).  
Other interesting examples of the utility of BM3 regard the conversion of terpene to perillyl alcohol or the 1-
hexane to 1,2-epoxy hexane.  
 
FIGURE 5. A) 1-hexene is converted to 1,2 epoxyhexane by BM3 triple mutants produced by saturation 
mutagenesis of the active site (Kubo 2006). B) Reaction performed by Ala264Val/Ala238Val/Lys437Phe 
BM3 triple mutant (Seifert 2011) C) I83M/I82T mutant of P450pyr catalysed reaction: hydroxylation of n-
butanol 1 to 1,4-butanediol. 
 
 
The huge protein engineering approach on BM3 is a versatile target able to perform different reactions useful 
in several fields.  
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However, using the chimera approach, interesting results have been obtained with CYP105D7, that 
is a class I type of CYP, that requires electrons provided through separated electron transfer proteins 
(ferredoxin and ferredoxin reductase) for the hydroxylation of 7-hydroxy-3-(4-hydroxyphenyl) 
chromen-4-one (Daidzein) an isoflavones. 
Joining the reductase partners and the CYP heme domain, the fusion enzyme obtained by Choi et al. 
(2012) catalyses hydroxylation of daidzein more efficiently, with a kcat/KM value of 16.8 µM-1 min-1 
and with very high regio-selectivity. 
  
 
FIGURE 6. The reaction catalised by 3’-ASDH. This fusion artificial enzyme hydroxylates the 3' 
of the daidzein B-ring (Choi 2012). 
 
Terminal hydroxylation of n-butanol to 1,4-butanediol, a useful reaction for industrial purposes 
(Barikani et al. 2009), have been reached with directed evolution, creating Iso83Met/Iso82Thr, a 
mutant of P450pyr monooxygenase (Yang et al. 2014) that represents a green route alternative to 
the synthetic traditional route for obtaining this product. This approach is fundamental in order to 
convert a hydrophilic compound that was not accepted by the class I wild-type enzyme. 
Another field of application for P450s is the production of hydroxy-fatty acids. The enzymatic 
oxidation catalysed by P450s on non-activated carbon is a great advantage in different industrial 
processes. They are widely used in different industrial fields, such as the chemical, food, cosmetic 
and biofuel industries. Hydroxy-fatty acids are often used as starting materials for the synthesis of 
resins, polymers, biopolymers, and there is evidence that these polymers, synthesized from hydroxy 
fatty acids, are much more resistant and flexible than petroleum-derived ones (Burdock et al. 2006).  
10- and 12-hydroxystearic acid is used in the manufacturing of lubricants, ricinoleic acid in soaps 
and also in the textile industry (Mutlu and Meier 2010). Due to the hydroxylation, fatty acids are 
more stable, more reactive and more solvent miscible, in comparison to non-hydroxylated fatty 
acids (Metzger and Bornscheuer 2006).  
Another interesting P450 from Bacillus megaterium, with potential biotechnological application, is 
CYP106A2, a NADPH dependent protein composed of a FMN domain (megaredoxin reductase) and an iron-
 20 
sulphur protein (megaredoxin). It is able to hydroxylate various 3-oxo-D4-steroids, mainly at the 15ß –
position. These hydroxylated products are very important in the pharmaceutical industry, and they are 
precursors in the synthesis of several steroids compounds. Moreover, Bleif and co-workers have also 
reported its ability to perform one-step regioselective reaction of the anti-inflammatory pentacyclic triterpene 
11-keto-β-boswellic acid (KBA), and to our knowledge this is the first reported pentacyclic triterpene 
conversion performed by a prokaryotic P450. They have also reported a whole-cell system using Bacillus 
megaterium strain MS941 for the conversion of KBA, with a 15-fold increase in comparison with the 
naturally CYP106A2 expressing Bacillus megaterium strain (ATCC 13368). 
6. CONCLUSIONS 
The flexibility of P450 enzymes in the recognition of different substrates, the possibility of generating or 
detecting industrial relevant metabolites, as well as the use of these enzymes in environmental detoxification, 
are the main reasons that have made these enzymes mature as useful biocatalysts. Every year more new 
enzymes are discovered from different kingdoms of life, lately even from viruses (Nelson 2009). An intense 
study of their electron transfer chain, especially for self-sufficient enzymes that display the highest efficiency 
in catalysis, important in biotechnological applications. Also relevant is the design of new, artificial, self-
sufficient enzymes, that overcome possible limitations of the P450 catalytic unit. Biotechnological 
applications, involving P450 monooxygenases, are nowadays becoming more of a reality, but further work 
should be focused on key aspects, such as improving the stability of the P450s and cofactor regeneration 
during biocatalysis. The development of efficient and self-sufficient P450s opens up new horizons in the 
field of the synthesis of new molecules, pro-drug activation, bioremediation and whole-cell applications.  
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